The level of proteins involved in Aβ clearance, TTR, apolipoprotein A1 (ApoA1), and complement component 3 (C3) in the blood are decreased in MCI and AD, and composite markers consisting of these three proteins had a high clinical potential to discriminate cognitive impairment from non-demented individuals in a multicentered clinical study [93,94]. This evidence concerns the gene APOA1 and Alzheimer disease.